Announcements Trials
Browse Landscape

Phase

Phase 3 1Phase 1/2 1Phase 1 1

Status

Recruiting 2Active not recruiting 1

Sponsor Class

OTHER 5INDUSTRY 3

Study Type

Interventional 3

Sponsor

Cancer Type

Other hematologic neoplasm 3Sarcoma 1

Conditions

Leukemia, Myeloid, Acute 3Leukemia 2Sarcoma, Myeloid 1Recurrence 1Hematologic Neoplasms 1

Interventions

pembrolizumab 302Carboplatin 230Cisplatin 159Paclitaxel 153Gemcitabine 153Pemetrexed 122Bevacizumab 121Docetaxel 105durvalumab 83Oxaliplatin 82Nivolumab 82Dexamethasone 80atezolizumab 79Fluorouracil 79Cyclophosphamide 79130-nm albumin-bound paclitaxel 74Fulvestrant 72Capecitabine 67Injections 66Cetuximab 64Leucovorin 63Rituximab 57fludarabine 52Lenalidomide 51venetoclax 47Prednisone 45Irinotecan 42enzalutamide 41Letrozole 41tislelizumab 38

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

3 trials
RecentStart dateEnrollment
INDUSTRY × quizartinib × 90 days × Clear all
NCT06578247 2026-04-30

QuANTUM-WILD

Daiichi Sankyo

Phase 3 Recruiting
700 enrolled
Other hematologic neoplasm

Leukemia, Leukemia, Myeloid, Acute

NCT03793478 2026-04-01

Safety and Efficacy of Quizartinib in Children and Young Adults With Acute Myeloid Leukemia (AML), a Cancer of the Blood

Daiichi Sankyo

Phase 1/2 Active not recruiting
65 enrolled
Other hematologic neoplasm

Recurrence, Leukemia, Myeloid, Acute

NCT05735184 2026-03-13

A Study to Investigate the Safety and Tolerability of Ziftomenib in Combination With Venetoclax/Azacitidine, Venetoclax, 7+3, or 7+3+Quizartinib in Patients With AML

Kura Oncology, Inc.

Phase 1 Recruiting
420 enrolled
Other hematologic neoplasmSarcoma

Leukemia, Leukemia, Myeloid, Acute, Hematologic Neoplasms, Sarcoma, Myeloid

Data powered by HemOnc (CC BY 4.0) Colophon âš¡